Peptides Similar to Linaclotide

Peptides Related to Linaclotide#

Linaclotide is the first-in-class guanylate cyclase-C (GC-C) agonist for IBS-C and chronic constipation. As a gut-restricted cyclic peptide with both secretory and analgesic properties, it occupies a unique position in the treatment landscape. The most relevant comparison is with plecanatide (another GC-C agonist), followed by non-peptide agents used for similar indications.

Plecanatide (Trulance)#

Plecanatide is a 16-amino-acid synthetic peptide analog of uroguanylin, the second FDA-approved GC-C agonist. It was developed by Synergy Pharmaceuticals and approved in 2017 for CIC and in 2018 for IBS-C.

Mechanism comparison: Both linaclotide and plecanatide activate GC-C to increase cGMP, promote chloride/water secretion, and reduce visceral pain. The key difference is that plecanatide was designed with pH-dependent activation -- it has enhanced binding affinity at pH 5 (matching the proximal duodenum) and reduced activity at neutral pH. Linaclotide has pH-independent activity throughout the intestine.

Clinical efficacy: Both agents have demonstrated efficacy for IBS-C and CIC in phase 3 trials. No head-to-head trial exists. Cross-trial comparisons suggest similar effect sizes, though direct comparison is limited by differences in trial design and endpoint definitions.

Dosing: Plecanatide is dosed at 3 mg once daily for both IBS-C and CIC (simpler dosing). Linaclotide uses 290 mcg for IBS-C and 145 mcg (or 72 mcg) for CIC.

Safety: Both have diarrhea as the primary adverse effect and carry the same pediatric boxed warning. Diarrhea rates may be slightly lower with plecanatide, though cross-trial comparisons are unreliable.

Lubiprostone (Amitiza)#

Lubiprostone is a bicyclic fatty acid (not a peptide) that activates ClC-2 chloride channels on the apical surface of intestinal epithelial cells. FDA-approved for CIC (2006), IBS-C in women (2008), and opioid-induced constipation (2013).

Mechanism comparison: Lubiprostone acts on a different chloride channel (ClC-2) than linaclotide (CFTR via GC-C). It does not produce the extracellular cGMP that mediates linaclotide's visceral pain reduction. Thus, lubiprostone primarily addresses constipation without the analgesic component important for IBS-C.

Key trade-off: Linaclotide offers the dual benefit of secretory and analgesic effects, while lubiprostone has broader indications (including OIC) and twice-daily dosing flexibility but lacks the pain reduction mechanism.

Tegaserod (Zelnorm)#

Tegaserod is a 5-HT4 receptor agonist re-approved in 2019 for IBS-C in women under 65 without cardiovascular risk factors. It acts systemically by stimulating peristalsis and intestinal secretion through serotonin receptor activation.

Key difference: Tegaserod is a systemically absorbed small molecule with cardiovascular safety restrictions (originally withdrawn due to CV events), while linaclotide is a gut-restricted peptide with no systemic safety concerns.

Summary Comparison#

Related Reading#

• Linaclotide overview and research guide
• Linaclotide research evidence
• Linaclotide dosing protocols